Waker Bioscience has secured $100 million in funding from investors, marking a significant investment in the company's efforts within the rapidly evolving cell and gene therapy sector. This capital injection underscores confidence in the company's proprietary technology and its critical role in drug product safety assessment.
The company leads the way in providing comprehensive safety assessment of cell and gene therapy drug products. Utilizing its proprietary LTA-PCR technology, Waker Bioscience enables pharmaceutical clients to develop novel therapies that meet stringent regulatory safety requirements. Its full-service offerings include vital services such as Integration Site Analysis, On-/Off-Target Analysis, Vector Copy Number determination, and Vector Quality Control, all essential for ensuring the safety and efficacy of advanced therapeutic products.
This substantial funding round is anticipated to accelerate Waker Bioscience's strategic growth initiatives. The capital will primarily be used to expand its research and development capabilities, enhance its service infrastructure, and scale operations to meet the increasing demand for its specialized safety assessment solutions globally. Such investment is crucial for supporting the intricate and highly regulated development pathways of cell and gene therapies.
The investment positions Waker Bioscience to further solidify its leadership in the analytical services market for cell and gene therapy. With this funding, the company aims to continue advancing its technological platforms and expanding its capacity, thereby playing a pivotal role in facilitating the safe and effective introduction of groundbreaking therapies to patients worldwide.
